EphB6 Matched ELISA Antibody Pair Set,Human
Solid Phase Sandwich ELISA
Quantitative determination of Human EphB6
1. Capture Antibody 1.0 mg/mL of rabbit anti-EphB6 monoclonal antibody (in PBS, pH 7.4). Dilute to a working concentration of 2 μg/mL in CBS before coating. (Catalog: # 10197-R026)
2. Detection Antibody 0.5 mg/mL rabbit anti-EphB6 monoclonal antibody conjugated to horseradish-peroxidase (HRP) (in PBS, 50 % glycerol, pH 7.4). Dilute to working concentration of 0.5 μg/mL in detection antibody dilution buffer before use. (Catalog: # 10197-R031)
3. Standard Each vial contains 8 ng of recombinant EphB6. Reconstitute with 1 mL detection antibody dilution buffer. After reconstitution, store at -20℃ to -80℃ in a manual defrost freezer. A seven-point standard curve using 2-fold serial dilutions in sample dilution buffer, and a high standard of 0.6 ng/mL is recommended.
This EphB6 Matched ELISA Antibody Pair Set,Human is a solid phase sandwich ELISA for quantitative determination of Human EphB6 . It contains Human EphB6 capture antibody, Human EphB6 detector antibody
and a highly purified
recombinant Human EphB6 protein. This Pair Set is at affordable price for researchers.
This Matched ELISA Antibody Pair Set is shipped at ambient temperature.
Capture Antibody: Aliquot and store at -20℃ to -80℃ for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Detection Antibody: Protect it from prolonged exposure to light. Aliquot and store at -20℃ to -80℃ and for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.
Standard: Store lyophilized standard at -20℃ to -80℃ for up to 6 months from date of receipt. Aliquot and store the reconstituted Standard at -80℃ for up to 1 month. Avoid repeated freeze-thaw cycles.
Ephrins are divided into the ephrin-A (EFNA) class and the ephrin-B (EFNB) class based on their structures and sequence relationships. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. EphB6 is an unusual Eph receptor, lacking catalytic capacity due to alterations in its kinase domain. Interestingly, increased metastatic activity is associated with reduced EphB6 receptor expression in several tumor types, including breast cancer. This emphasizes the potential of EphB6 to act as a suppressor of cancer aggressiveness. EphB6 suppress cancer invasiveness through c-Cbl-dependent signaling, morphologic changes, and cell attachment and indicate that EphB6 may represent a useful prognostic marker and a promising target for therapeutic approaches. EphB6 can both positively and negatively regulate cell adhesion and migration, and suggest that tyrosine phosphorylation of the receptor by an Src family kinase acts as the molecular switch for the functional transition. In addition, Ephrin-B2 may be a physiological ligand for the EphB6 receptor.
Munthe E, et al. (2000)Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6. FEBS Lett. 466(1): 169-74.Matsuoka H, et al. (2005) Biphasic functions of the kinase-defective Ephb6 receptor in cell adhesion and migration. J Biol Chem. 280(32): 29355-63.Truitt L, et al. (2010) The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res. 70(3): 1141-53.